Baseline plasma matrix metalloproteinase 9 (MMP9) to predict overall survival (OS) benefit from bevacizumab (BEV) in newly diagnosed glioblastoma (GBM): Retrospective analysis of AVAglio.
2016 ◽
Vol 34
(15_suppl)
◽
pp. 2020-2020
◽
2010 ◽
Vol 129
(4)
◽
pp. 887-895
◽
2006 ◽
Vol 5
(1)
◽
pp. 79-80
2006 ◽
Vol 2006
◽
pp. 352-353